In 2019, we discovered a new breast cancer subtype: immune clusters, (Tekpli et al., Nature Communications, 2019), we clearly show how the information on immune infiltration in breast cancer is clinically applicable and relevant for treatment decision.
We invariably identified a group of patients with a poor prognosis (see figure below) and poor response to treatment: this group of breast cancers needs new personalized therapies.
We therefore researching on
- developing an assay to efficiently subtype breast cancer patients for immune clusters.
- identify test and validate new treatment strategies in pre-clinical setting.